Terms: = Lung cancer AND PDGFB, SIS, 5155, ENSG00000100311, FLJ12858, PDGF2, P01127, c-sis, SSV AND Prognosis
21 results:
1. Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma.
Yang W; Wu Z; Cai S; Li Z; Wang W; Wu J; Luo H; Ye X
Front Immunol; 2024; 15():1354339. PubMed ID: 38638428
[TBL] [Abstract] [Full Text] [Related]
2. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract] [Full Text] [Related]
3. Spatial features of specific CD103
Yang G; Cai S; Hu M; Li C; Yang L; Zhang W; Sun J; Sun F; Xing L; Sun X
J Transl Med; 2024 Jan; 22(1):27. PubMed ID: 38183111
[TBL] [Abstract] [Full Text] [Related]
4. Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer.
Sun QY; Zhou Y; Du LJ; Zhang MK; Wang JL; Ren YY; Liu F
Yi Chuan; 2023 Aug; 45(8):684-699. PubMed ID: 37609819
[TBL] [Abstract] [Full Text] [Related]
5. Neutrophils correlate with hypoxia microenvironment and promote progression of non-small-cell lung cancer.
Zhang C; Tang B; Hu J; Fang X; Bian H; Han J; Hou C; Sun F
Bioengineered; 2021 Dec; 12(1):8872-8884. PubMed ID: 34637697
[TBL] [Abstract] [Full Text] [Related]
6. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma.
Gao L; Zhang L
BMC Cancer; 2021 Jul; 21(1):849. PubMed ID: 34301211
[TBL] [Abstract] [Full Text] [Related]
7. Systemic Inflammatory Score Predicts Response and Prognosis in Patients With lung cancer Treated With Immunotherapy.
Zaitsu J; Yamashita Y; Ishikawa A; Saito A; Kagimoto A; Mimura T; Hirakawa T; Mito M; Fukuhara K; Senoo T; Nakano K; Kuraoka K; Taniyama K
Anticancer Res; 2021 Jul; 41(7):3673-3682. PubMed ID: 34230166
[TBL] [Abstract] [Full Text] [Related]
8. cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract] [Full Text] [Related]
9. Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell lung cancer.
Wang J; Hui Z; Men Y; Kang J; Sun X; Deng L; Zhai Y; Wang W; Bi N; Liang J; Lv J; Zhou Z; Feng Q; Xiao Z; Chen D; Wang L; Zhao J
Ann Thorac Surg; 2019 Dec; 108(6):1701-1709. PubMed ID: 31400325
[TBL] [Abstract] [Full Text] [Related]
10. Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD.
Dong W; Du Y; Ma S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3805-3812. PubMed ID: 30538442
[TBL] [Abstract] [Full Text] [Related]
11. [Preliminary study of exon sequence in pneumoconiosis and pneumoconiosis complicated with lung cancer using high-throughput sequencing technology].
Jiang MF; Li L; Wang Z; Zhang CL; Zhang H
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Nov; 35(11):801-806. PubMed ID: 29316748
[No Abstract] [Full Text] [Related]
12. Fibroblast-led cancer cell invasion is activated by epithelial-mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma.
Neri S; Miyashita T; Hashimoto H; Suda Y; Ishibashi M; Kii H; Watanabe H; Kuwata T; Tsuboi M; Goto K; Menju T; Sonobe M; Date H; Ochiai A; Ishii G
Cancer Lett; 2017 Jun; 395():20-30. PubMed ID: 28286261
[TBL] [Abstract] [Full Text] [Related]
13. GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer.
Bu L; Zhang LB; Mao X; Wang P
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323109
[TBL] [Abstract] [Full Text] [Related]
14. Clinical value of ultrasound-guided percutaneous biopsy of pulmonary lesions.
Yang RJ; Yang YL; Ruan LT; Yuan LJ; Chao LJ; Chen S; Duan YY
Genet Mol Res; 2015 Apr; 14(2):3784-90. PubMed ID: 25966148
[TBL] [Abstract] [Full Text] [Related]
15. Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion.
Chen CD; Wang CL; Yu CJ; Chien KY; Chen YT; Chen MC; Chang YS; Wu CC; Yu JS
J Proteome Res; 2014 Jun; 13(6):2818-29. PubMed ID: 24787432
[TBL] [Abstract] [Full Text] [Related]
16. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer.
Donnem T; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
Ann Oncol; 2010 Feb; 21(2):223-231. PubMed ID: 19628565
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
Donnem T; Al-Saad S; Al-Shibli K; Andersen S; Busund LT; Bremnes RM
J Thorac Oncol; 2008 Sep; 3(9):963-70. PubMed ID: 18758297
[TBL] [Abstract] [Full Text] [Related]
19. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract] [Full Text] [Related]
20. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract] [Full Text] [Related]
[Next]
